Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?

Sabbioni, Marzio E E; Bernhard, Jürg; Siegrist, Hans-Peter; Schmitz, Shu-Fang Hsu; Gertsch, Monica Castiglione; Thürlimann, Beat; Bonnefoi, Hervé; Perey, Lucien; Herrmann, Richard; Goldhirsch, Aron; Hürny, Christoph; Swiss Group for Clinical Cancer Research, (SAKK) (2004). Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy? Breast cancer research and treatment, 87(1), pp. 75-86. Dordrecht: Springer 10.1023/B:BREA.0000041584.53863.a7

Preview

Text Sabbioni2004_Article_DoesSubjectiveBurdenOfEarlyBre.pdf - Published Version Available under License Publisher holds Copyright. Download (306kB) | Preview

Psychosocial factors have been described as affecting cellular immune measures in healthy subjects. In patients with early breast cancer we explored bi-directional psycho-immune effects to determine whether subjective burden has an impact on immune measures, and vice versa. Patients (n = 239) operated for early breast cancer and randomized into International Breast Cancer Study Group (IBCSG) adjuvant clinical trials were assessed immediately before the beginning of adjuvant treatment (baseline) and 3 and 6 months thereafter, at the beginning of the corresponding treatment cycle. Cellular immune measures (leukocytes, lymphocytes, lymphocyte subset counts), markers of activation of the cellular immune system (beta2-microglobulin, soluble interleukin-2 receptor serum levels), and self-report subjective burden (global indicators of physical well-being, mood, coping effort) were assessed concurrently. The relationship between subjective burden and gradients of immune measures was investigated with regression analyses controlling for adjuvant treatment. There was a pattern of small negative associations between all variables assessing subjective burden before the beginning of adjuvant therapy with the gradients of the markers of activation of the cellular immune system and NK cell counts. In particular, better mood predicted a decline in the course of beta2-microglobulin and IL-2r at months 3 and 6. The gradient of beta2-microglobulin was associated with mood and coping effort at month 3. However, the effect sizes were very small. In conclusion, in this explorative investigation, there was an indication for subjective burden affecting and being affected by markers of activation of the cellular immune system during the first 3 and 6 months of adjuvant therapy. The question of clinical significance remains unanswered. These associations have to be investigated with refined assessment tools and schedules.

Interest & Impact

Downloads

64 since deposited on 04 Oct 2013
25 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item